Skip to content
July 18, 2018

Cash position and activity update for H1 2018 and key perspectives for the end of 2018

 

  • Solid cash position of €13.5 million at June 30, 2018
  • Key highlights of H1 2018: primary objective met in the first results of TARGET PHASE II study and with the strategic partnership with the University of North Texas Health Science Center
  • Key perspectives by the end of 2018: results of TANGO PHASE III study with CER-001 with HDL deficiency patients and PHASE I study of repeated and increasing doses to assess CER-209 in NASH/NAFLD NAFLD/NASH 
Toulouse, FRANCE, Lakeland, UNITED-STATES, July 18, 2018, 6.00 pm CEST – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and HDL platform technologies today recapitulates the major events previously communicated and announced its cash position at June 30, 2018 and perspectives for the end of 2018.

Please find the complete press release here.
About Cerenis: www.cerenis.com
CERENIS Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids is removed from arteries and is transported to the liver for elimination from the body.

CERENIS is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Capitalizing on its expertise, Cerenis is developing the first HDL-based targeting drug delivery platform dedicated to the oncology field (immuno-oncology and chemotherapy).

CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.